Sun.Dec 04, 2022

article thumbnail

Humira biosimilars set the stage for long-awaited 2023 US launches

Pharmaceutical Technology

Starting in January, multiple biosimilars of AbbVie’s blockbuster drug Humira are set to flood the US pharmaceutical market.

Pharmacy 218
article thumbnail

Elon Musk’s Neuralink brain interface chip set for human trials

Pharma Phorum

Clinical trials of a wireless brain chip developed by Elon Muck’s Neuralink company will be tested in human volunteers within the next six months – and Musk himself says he intends to have one implanted for a future demo event.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Protracted Job Searches Exact Weighty Mental Health Toll

BioSpace

Whether a job search is voluntary or not, the psychological toll of months of interviews, wrangling over pay and benefits and evaluating options has a weighty psychological toll

75
article thumbnail

Addressing leadership barriers for women in tech and pharma

Pharma Phorum

Contrary to Big Tech, historically the pharmaceutical industry has had a good reputation for being a female-positive industry. However, both industries share a common problem: failure to provide women with C-suite opportunities.

article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

article thumbnail

FUJIFILM Diosynth Biotechnologies: There’s a New Cell Therapy Employer in Thousand Oaks

BioSpace

FUJIFILM Diosynth Biotechnologies is offering unique opportunities to join one of the top global CDMOs focused on solving some of the most complex healthcare challenges

70
article thumbnail

Sanofi, Amgen acknowledge Horizon interest as J&J steps back

Pharma Phorum

Amgen and Sanofi have said they may make cash-only offers for Horizon Therapeutics, which confirmed it was in talks with potential buyers last week, but Johnson & Johnson has ruled itself out of the running.

More Trending

article thumbnail

Amgen to push latecomer obesity drug into midstage testing

Pharma Phorum

Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2 programme for the drug next year.

article thumbnail

FDA Outlines Path Forward for Verve’s Lead Candidate, VERVE-101

BioSpace

Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101

67
article thumbnail

New patent expiration for Allergan drug VIIBRYD

Drug Patent Watch

Annual Drug Patent Expirations for VIIBRYD Viibryd is a drug marketed by Allergan and is included in one NDA. It is available from four suppliers. There are four patents protecting…. The post New patent expiration for Allergan drug VIIBRYD appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Janssen Bows Out as Contender for Horizon Therapeutics Buyout

BioSpace

Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. This leaves Amgen and Sanofi at the bidding table

66
article thumbnail

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are….

article thumbnail

In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise

BioSpace

Novartis announced the Phase III PSMAfore trial of Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer met its primary endpoint

Trials 59
article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four….

article thumbnail

Novo Nordisk & ATLATL announce winners in their joint program EntreStar Novo Nordisk Research Centre China and ATLATL jointly announce the winners of EntreStar program. Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) Innovent Biologics, Inc. and UNION therapeutics A/S announced that the first Chinese healthy volunteer has been successfully dosed in the Phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical Phase II stage. Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device at AES 2022 Seoul National University Bundang Hospital presented its preliminary study result of seizure monitoring for patients with epilepsy using SK Biopharmaceuticals' multimodal wearable device at the American Epilepsy Society Annual Meeting 2022 in Nashville, Tennessee, December 2-6. Pictor announces funding round after successful launch in

BioSpace

TauRx Pharmaceuticals and Anavex Life Sciences presented positive results from their candidates at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco, CA

article thumbnail

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

article thumbnail

Sex, Racial, and Ethnic Representation in COVID-19 Clinical Trials

JAMA Internal Medicine

This systematic review and meta-analysis investigates whether female participants and racial and ethnic minority individuals are adequately represented in COVID-19 prevention and treatment trials in the US

article thumbnail

Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization?

Drug Patent Watch

This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions. Infographic

Drugs 40
article thumbnail

Abandoned Housing Interventions and Gun Violence, Perceptions of Safety, and Substance Use

JAMA Internal Medicine

This cluster randomized controlled trial assesses whether abandoned house remediation reduces gun violence and substance-related outcomes and increases perceptions of safety and use of outdoor space in low-income, Black neighborhoods

article thumbnail

Financial Incentives for Weight Loss Among Patients With Obesity in Disadvantaged Neighborhoods

JAMA Internal Medicine

This randomized clinical trial examines the effects of 2 financial incentive strategies among patients with obesity living in low-income neighborhoods

article thumbnail

Pneumococcal Conjugate Vaccine Use and Hospitalized Pneumonia in Medicare Beneficiaries With/Without Medical Conditions

JAMA Internal Medicine

This cohort study examines the association of 13-valent pneumococcal conjugate vaccine use with pneumonia, non–health care–associated pneumonia, and lobar pneumonia (LP) hospitalization among US Medicare beneficiaries 65 years or older